Pacanalotamab

Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines[1].

Product Specifications

CAS Number

[2251756-52-0]

Product Name Alternative

AMG 420; BI-836909

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pacanalotamab.html

Purity

97.04

Solubility

10 mM in DMSO

Smiles

[Pacanalotamab]

Molecular Weight

(53.69 kDa)

References & Citations

[1]Hipp S, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017 Aug;31 (8) :1743-1751.